AMANDA COMBS: Open Payments
NPI 1881133585 · RICHLANDS, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,160 in 145 payments from 26 companies in 2025. Trend: 2023 $1,263 · 2024 $2,028 · 2025 $2,160
Food & beverage: $2,160
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 43 | $410 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $311 |
| AstraZeneca Pharmaceuticals LP | 7 | $176 |
| Amgen Inc. | 26 | $174 |
| GlaxoSmithKline, LLC. | 10 | $164 |
| Novo Nordisk Inc | 9 | $142 |
| Regeneron Healthcare Solutions, Inc. | 4 | $103 |
| Vanda Pharmaceuticals Inc. | 5 | $98 |
| Exact Sciences Corporation | 4 | $86 |
| Novartis Pharmaceuticals Corporation | 3 | $65 |
Products named: CAPLYTA, TRELEGY ELLIPTA, VRAYLAR, UBRELVY, QULIPTA, FARXIGA, DUPIXENT, OTEZLA.
Industry payments across VA — which companies pay providers there.
